ACTU
Actuate Therapeutics IncHealthcare · $17M market cap
Verdict
We can't put a fair value on ACTU right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Follow ACTU
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 28, 2026: 2 open-market purchases worth $82K. Why purchases matter
Purchases
Questions about ACTU
Are insiders buying ACTU?
Since Oct 28, 2026: 2 open-market purchases worth $82K.
How can I check ACTU's value myself?
Use the free Sticker Price calculator, already filled with ACTU's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 29, 2026. How the Payback Price works